Navigating The Journey from Bench to Bedside
Therapeutic antibodies continue to change how we treat human diseases. But antibody discovery and optimization present several challenges and the overwhelming majority of leads that enter pre-clinical testing will fail to navigate the twists and turns on the path to market. Even highly potent and specific candidates can have suboptimal developability profiles and face downstream aggregation, stability, formulation, or manufacturing problems.
Using our best-in-class discovery platform, Twist Biopharma’s antibody experts have discovered and vetted an array of lead antibodies against high-value targets, saving you the trouble of launching your own discovery projects and dealing with these problems internally. These fully human, IgG leads are engineered for developability, de-risked for common downstream liabilities, and built on a partnership aimed at accelerating your journey from bench to bedside.
Best-in-Class Therapeutics Start With a Best-in-Class Discovery Platform
Our unique, high-quality DNA writing platform allows us to design diverse antibody variants, with base-by-base precision. Using that as our foundation, we’ve built a best-in-class discovery platform, which served as the starting point for the antibody leads above. Each discovery project was led by our internal team of experts, with over 50 years of combined experience in therapeutic antibody development.
Enrich Your Pipeline With Antibodies Discovered and Vetted by Our Experts
Our library of libraries and internal expertise has enabled the discovery and selection of leads against challenging drug targets, like GLP-1R and ADORA2A. Once selected, each lead goes through our IgG conversion, expression, and purification and our high-throughput developability workflow to assess downstream pre-clinical success.
Testimonial
Rapidly Reach Clinical Milestones
Our precision DNA writing platform removes downstream development and manufacturing liabilities and unwanted motifs from our libraries. The antibody leads are de-risked through our developability risk assessment, saving you costly and time-consuming rework and giving you the greatest probability of hitting your development and clinical milestones.
Partnering to Accelerate Your Time to Market
Twist Biopharma is your specialty partner for antibody discovery, optimization, and development projects. Our flexible team has led first-in-class discovery and development projects and is equipped to find a broad range of solutions to your unique situation, whether it be additional analysis of our characterized antibody leads, initiating custom library construction, or optimizing leads from other discovery platforms.
See Which Therapeutic Targets We’ve Unlocked
